Cosmo Bio Co., Ltd. AI Stock Analysis
Want to see JP:3386 full AI Analyst Report?
Cosmo Bio Co., Ltd. (3386) AI Stock Analysis
Cosmo Bio Co., Ltd.
(TSE/TYO:3386)
The overall score is driven primarily by the company's exceptional balance sheet stability and an attractive 4.07% dividend yield. However, the stock is currently weighed down by negative technical momentum and fundamental challenges regarding margin compression. Sustained improvements in operational efficiency will be required to break the current bearish price trend.
Cosmo Bio Co., Ltd. (3386) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.98B
- Dividend Yield
- 4.07%
- Average Volume (3M)
- 4,050
- Price to Earnings (P/E)
- 21.2
- Beta (1Y)
- 0.29
- Revenue Growth
- 7.17%
- EPS Growth
- 36.23%
- Country
- Japan
- Employees
- 182
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Cosmo Bio Co., Ltd. Business Overview & Revenue Model
Company Description
Cosmo Bio Company, Limited is a key player in the life science research sector, involved in the global import, export, manufacturing, marketing, and distribution of essential biotools. Their extensive product line includes biochemical reagents, speci...
Cosmo Bio Co., Ltd. Financial Statement Overview
Summary
Anchored by a pristine, debt-free balance sheet and recovering cash flows. While top-line revenue has reached record highs, the score is constrained by multi-year margin compression and efficiency challenges.
Income Statement
55NeutralBalance Sheet
88Very PositiveCash Flow
72Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.27B | 10.77B | 10.04B | 9.34B | 9.55B | 9.23B |
| Gross Profit | 3.89B | 3.70B | 3.33B | 3.25B | 3.44B | 3.66B |
| EBITDA | 515.00M | 509.00M | 455.00M | 801.00M | 931.00M | 1.26B |
| Net Income | 328.00M | 336.00M | 262.00M | 442.00M | 517.00M | 737.00M |
Balance Sheet | ||||||
| Total Assets | 12.18B | 12.66B | 11.72B | 10.87B | 10.31B | 10.07B |
| Cash, Cash Equivalents and Short-Term Investments | 4.08B | 2.95B | 2.69B | 3.02B | 3.04B | 3.56B |
| Total Debt | 20.00M | 20.00M | 22.00M | 24.00M | 27.00M | 28.00M |
| Total Liabilities | 2.29B | 2.70B | 2.17B | 1.84B | 1.69B | 1.75B |
| Stockholders Equity | 9.30B | 9.37B | 8.97B | 8.45B | 8.05B | 7.79B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 366.00M | 25.00M | 636.00M | 180.00M | 507.00M |
| Operating Cash Flow | 0 | 595.00M | 241.00M | 736.00M | 284.00M | 648.00M |
| Investing Cash Flow | 0 | 43.00M | -217.00M | -758.00M | -291.00M | -145.00M |
| Financing Cash Flow | 0 | -283.00M | -479.00M | -201.00M | -236.00M | -420.00M |
Cosmo Bio Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3386, the sentiment is Negative. The current price of 1230.00 is below the 20-day moving average (MA) of 1230.85, below the 50-day MA of 1244.44, and below the 200-day MA of 1252.31, indicating a bearish trend. The MACD of -5.72 indicates Negative momentum. The RSI at 47.29 is Neutral, neither overbought nor oversold. The STOCH value of 75.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3386.
Cosmo Bio Co., Ltd. Peers Comparison
Overall Rating
JP:457070Outperform- JP:338667Neutral
JP:497847Neutral
JP:489242Neutral
JP:777639Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4570 | 70Outperform | JPY 9.07B | 23.55 | ― | 0.64% | 7.10% | 17.17% |
| JP:3386 | 67Neutral | JPY 7.11B | 21.17 | ― | 4.07% | 7.17% | 36.23% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4978 | 47Neutral | JPY 12.29B | -23.75 | ― | ― | -8.23% | -48.10% |
| JP:4892 | 42Neutral | JPY 5.50B | -6.45 | ― | ― | 364.72% | 18.43% |
| JP:7776 | 39Underperform | JPY 6.78B | -5.83 | ― | ― | -56.16% | 3.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:3386 | Cosmo Bio Co., Ltd. | 1230.00 | -153.89 | -11.12% | |
| JP:4570 | Immuno-Biological Laboratories Co., Ltd. | 917.00 | 69.63 | 8.22% | |
| JP:4892 | Cyfuse Biomedical K.K. | 514.00 | -67.00 | -11.53% | |
| JP:4978 | ReproCELL Inc. | 109.00 | -48.00 | -30.57% | |
| JP:7776 | CellSeed Inc. | 169.00 | -232.00 | -57.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026